Synergistic drug combination effectively blocks Ebola virus infection

详细信息    查看全文

• 作者：Wei Sun^a ; ¹ ; Shihua He^b ; ^c ; ¹ ; Carles Mart&iacute ; nez-Romero^d ; ^e ; ¹ ; Jennifer Kouznetsova^a ; Gregory Tawa^a ; Miao Xu^a ; Paul Shinn^a ; Ethan G. Fisher^a ; Yan Long^a ; Omid Motabar^a ; Shu Yang^a ; Philip E. Sanderson^a ; Peter R. Williamson^f ; Adolfo Garc&iacute ; a-Sastre^d ; ^e ; ^g ; ^{Adolfo.Garcia-Sastre@mssm.edu} ; Xiangguo Qiu^b ; ^c ; ^{xiangguo.qiu@phac-aspc.gc.ca} ; Wei Zheng^a ; ^{wzheng@mail.nih.gov}
• 关键词：Ebola treatment ; Ebola prevention ; Drug combination ; Drug repurposing ; Polypharmacology
• 刊名：Antiviral Research
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：137
• 期：Complete
• 页码：165-172
• 全文大小：2322 K
• 卷排序：137

文摘

Drug combinations may enable clinical application by reducing individual drug concentrations for inhibiting EBOV infection. 795 pairs of three-drug combinations of FDA-approved drugs were screened for anti-Ebola virus activity. Two sets of clinical useful three-drug combinations were validated for inhibition of live Ebola virus infection. Mechanisms of action of these drugs were identified in affecting host-pathogen interactions.